


## Cevidopenib dimesylate

<b>Cat. No.:</b>	HY-109082A
<b>CAS No.:</b>	2043659-93-2
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>35</sub> N <sub>7</sub> O <sub>9</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	665.74
<b>Target:</b>	Syk
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (37.55 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.5021 mL	7.5104 mL	15.0209 mL
<b>5 mM</b>			0.3004 mL	1.5021 mL	3.0042 mL	
	<b>10 mM</b>		0.1502 mL	0.7510 mL	1.5021 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.76 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.76 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Cevidopenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities <sup>[1][2]</sup> .
--------------------	--

### REFERENCES

- [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 31, No. 4, 2017.
- [2]. cevidopenib dimesylate.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA